Even before we discuss the impact of Artificial Intelligence on Immigration, its important to understand on how countries benefit from Immigration.Every country wants to attract best talent in the world. Talented citizens will help generate further jobs and expand economy. Skilled labour is always in demand and hence almost every country has immigration program for skilled labour. Now on Artificial Intelligence- development of computer systems that are able to perform tasks that normally require human intelligence. Some of the recent Artificial Achievement advancements in various industries:Healthcare Major medical and pharmaceutical companies are already harnessing the power of artificial intelligence with great results.

Segway creator Dean Kamen's Luke prosthetic arm has been a long time in coming -- the FDA approved it two years ago. Mobius Bionics has revealed that it will offer the Luke arm sometime in late 2016. It's not clear what it will take to get one (you can register your interest today), but the features remain the same. The bionic wearable is all about offering the life-like dexterity that hasn't really been an option until now: you can hold a glass over your head without spilling it, for example, and the hand's mix of four motors and grip sensors can help you grab both very delicate and very heavy items. The odds are that getting one won't be trivial, but it might well be justified if it grants some extra freedom.

Stealthy MedyMatch emerged in February with plans to improve emergency room care using cognitive analysis and artificial intelligence. Now, in its first collaboration with a U.S. hospital, the company is developing its first real-time decision-support tool using data from New Jersey-based Capital Health. Under the agreement, Capital Health will supply Israel-based MedyMatch with anonymized data to help it develop the tool, which will target stroke patients. It will analyze medical images and provide the ER radiologist with information to help him or her determine the course of treatment. It combines "deep vision, advanced cognitive analytics and artificial intelligence" to analyze images and identify anomalies that may be invisible to the human eye.

Artificial intelligence may be the new face of medical diagnostics. For the first time, a flavor of A.I. called deep learning is being implemented in new ultrasound imaging equipment to aid in breast exams and help patients avoid unnecessary biopsies. A new feature in Samsung Medison's ultrasound system uses a deep-learning algorithm to make recommendations about whether a breast abnormality is benign or cancerous. The "S-Detect for Breast" feature is now included in an upgrade to the company's RS80A ultrasound system and is commercially available in parts of Europe, the Middle East and Korea and is pending FDA approval in the U.S., according to PR manager Doug Kim. Deep learning relies on large amounts of data to inform complex decision-making algorithms, has aided in everything from speech and image recognition software to pharmaceutical research.

Samsung Medison's new ultrasound system quickly screens for abnormalities. Artificial intelligence may be the new face of medical diagnostics. For the first time, a flavor of A.I. called deep learning is being implemented in new ultrasound imaging equipment to aid in breast exams and help patients avoid unnecessary biopsies. A new feature in Samsung Medison's ultrasound system uses a deep-learning algorithm to make recommendations about whether a breast abnormality is benign or cancerous. The "S-Detect for Breast" feature is now included in an upgrade to the company's RS80A ultrasound system and is commercially available in parts of Europe, the Middle East and Korea and is pending FDA approval in the U.S., according to PR manager Doug Kim.

In the future, will artificial intelligence be so sophisticated that it will be able to tell when someone is trying to deceive it? A Carnegie Mellon University professor and his team is working on technology that could move this idea from the realm of science fiction to reality. Their work -- rooted in game theory and machine learning -- is part of a larger push for more advanced AI. As AI becomes more commonplace in the technology we use every day, detractors and supporters are becoming more vocal about its potential risks and benefits. For some, smarter AI sets up a dangerous precedent for a future too reliant on machines to make decisions about everything from medical diagnoses to the operation of self-driving cars.

In the future, will artificial intelligence be so sophisticated that it will be able to tell when someone is trying to deceive it? A Carnegie Mellon University professor and his team is working on technology that could move this idea from the realm of science fiction to reality. Their work -- rooted in game theory and machine learning -- is part of a larger push for more advanced AI. As AI becomes more commonplace in the technology we use every day, detractors and supporters are becoming more vocal about its potential risks and benefits. For some, smarter AI sets up a dangerous precedent for a future too reliant on machines to make decisions about everything from medical diagnoses to the operation of self-driving cars.

BPM 31510 is just another cancer drug in human development trials, except for one thing. Scientists didn't toil away in labs to come up with it; artificial intelligence did. The cancer drug development process is costly and time-consuming. On average, it takes 24 to 48 months and upwards of 100 million to find a suitable candidate. Add that to the fact that 95% of all potential drugs fail in clinical trials, and the inefficiencies of the whole drug-discovery machine really become apparent.

A key goal of computational personalized medicine is to systematically utilize genomic and other molecular features of samples to predict drug responses for a previously unseen sample. Such predictions are valuable for developing hypotheses for selecting therapies tailored for individual patients. This is especially valuable in oncology, where molecular and genetic heterogeneity of the cells has a major impact on the response. However, the prediction task is extremely challenging, raising the need for methods that can effectively model and predict drug responses. In this study, we propose a novel formulation of multi-task matrix factorization that allows selective data integration for predicting drug responses. To solve the modeling task, we extend the state-of-the-art kernelized Bayesian matrix factorization (KBMF) method with component-wise multiple kernel learning. In addition, our approach exploits the known pathway information in a novel and biologically meaningful fashion to learn the drug response associations. Our method quantitatively outperforms the state of the art on predicting drug responses in two publicly available cancer data sets as well as on a synthetic data set. In addition, we validated our model predictions with lab experiments using an in-house cancer cell line panel. We finally show the practical applicability of the proposed method by utilizing prior knowledge to infer pathway-drug response associations, opening up the opportunity for elucidating drug action mechanisms. We demonstrate that pathway-response associations can be learned by the proposed model for the well known EGFR and MEK inhibitors.

The U.S. Food and Drug Administration (FDA) has just approved the first medical robot from Auris Surgical, a stealthy startup led by the co-founder of industry leader Intuitive Surgical, makers of the widely-used da Vinci robot. The teleoperated ARES robot (the acronym stands for Auris Robotic Endoscopy System), was cleared by the FDA at the end of May, and could now be used for diagnosing and treating patients. Auris, which describes itself only as a "technology company based in Silicon Valley," was previously thought to be working on a robotic microsurgical system designed to remove cataracts, and the company has in fact filed several patent applications along those lines. However, an investigation by IEEE Spectrum suggests that the company has greater ambitions, including, according to current and former employees, "building the next generation of surgical robots… capable of expanding the applicability of robotics to a broad spectrum of medical procedures." A close reading of recent patent applications filed by Auris scientists shows that the company is focusing on so-called endolumenal (or endoluminal) surgery.